| Company Name: |
LGM Pharma |
| Tel: |
1-(800)-881-8210 |
| Email: |
inquiries@lgmpharma.com |
- Tazanolast
-
- $1520.00
-
2026-05-11
- CAS:82989-25-1
- Purity:
- Supply Ability: 10g
|
| | Tazanolast Basic information |
| Product Name: | Tazanolast | | Synonyms: | butyl 2-oxo-2-[3-(2H-tetrazol-5-yl)anilino]acetate;Butyl 3'-(1H-tetrazol-5-y1)oxanilate;Tazalest;Tazanol;TO-188;N-[3-(1H-Tetrazol-5-yl)phenyl]oxamidic acid butyl ester;Oxo[[3-(1H-tetrazol-5-yl)phenyl]amino]acetic acid butyl ester;WP-833 | | CAS: | 82989-25-1 | | MF: | C13H15N5O3 | | MW: | 289.29 | | EINECS: | | | Product Categories: | | | Mol File: | 82989-25-1.mol |  |
| | Tazanolast Chemical Properties |
| density | 1.343 | | storage temp. | 2-8°C | | solubility | Soluble in DMSO | | pka | 4.06±0.10(Predicted) | | form | Solid | | color | White to off-white |
| | Tazanolast Usage And Synthesis |
| Description | Tazanolast is an orally active antiallergic agent useful in the treatment of bronchial
asthma and nasal allergy. Mechanistically it appears to inhibit IgG and IgE-mediated
antigen-antibody reactions. | | Chemical Properties | White or yellowish-white crystal or crystalline powder, slightly odor, bitter taste. Soluble in acetone, soluble in methanol, ethanol or acetonitrile, insoluble in ether, insoluble in water. Acute toxicity LD50 male and female mice, male and female rats (mg/kg): >4000, >4000, >4000, >4000 orally; >4000, >4000, >4000, >4000 subcutaneously; 1145, 1191, 1423, 1528 intraperitoneally; 1126, 1121, 1119, 1277 intravenously. | | Originator | Wakamoto (Japan) | | Uses | TAZANOLAST is used for bronchial asthma. | | Definition | ChEBI: Tazanolast is an organic molecular entity. | | Brand name | Tazalest; Tazanol |
| | Tazanolast Preparation Products And Raw materials |
|